US Patent 11,896,719: What the Claims Cover and Where the Landscape Tightens
US Drug Patent 11,896,719 is directed to methods of treating IgA nephropathy using an oral budesonide formulation that is engineered for gastroresistance and ileum targeting via (i) an enteric capsule and (ii) extended-release core coating made from a specific ethylcellulose / hydroxypropylmethyl cellulose (HPMC) polymer blend with defined loading and dissolution thresholds under USP <711> Apparatus 2 (paddle, 100 rpm). The claim set then narrows further to percent release to the ileum region, and to specific simulation media conditions, including Level 1 Fasted State Simulated Intestinal Fluid (FaSSIF) at pH 6.5 and phosphate buffer at pH 6.8, with a stated surfactant level.
What matters commercially is that the enforceable scope is not “budesonide for IgA nephropathy.” It is budesonide for IgA nephropathy delivered with a very specific release engineering profile: tight caps on acid exposure release (pH 1.2), strict early-release limits at intestinal pH, and a defined extended-release polymer blend composition and fraction of the coated core.
Claim Architecture: How the Patent Narrows from Product Mechanism to Engineering Specs
Core dependent structure
The independent claims (as provided) are two parallel independent formulations that differ primarily in the permitted ethylcellulose/HPMC blend window and tied subranges.
- Claim 1:
- Core: budesonide
- Core coating: extended-release polymer blend = ethylcellulose ~51.8 wt.% and HPMC ~27.3 wt.% (of the polymer blend)
- Polymer blend fraction: 5 wt.% to 18 wt.% of total coated core weight
- Dosage form: capsule with enteric coating at 34 mg to 46 mg per capsule
- Release test: USP <711> Apparatus 2, paddle 100 rpm
- pH 1.2 (aqueous): ≤10% released by 120 min
- pH 6.5 FaSSIF Level 1 or pH 6.8 phosphate buffer:
- ≤10% released by 30 min
- ≥70% released by 120 min
- Dosing: daily dose ~16 mg budesonide
- Claim 7: same concept and same dissolution/dose structure, but with expanded polymer windows:
- Ethylcellulose 47 wt.% to 56 wt.%
- HPMC 32 wt.% to 22 wt.%
- Polymer blend fraction: 5 wt.% to 18 wt.% of total coated core weight
- Same enteric coating mass window and same in vitro release criteria
- Daily dose ~16 mg
Second layer: ileum-region outcome (dependent claims)
- Claims 2-4 / 10-12: require “substantially released” to the ileum region plus quantitative thresholds:
- ≥60% of initial content released to ileum (claim 3 and claim 11)
- ≥90% of initial content released to ileum (claim 4 and claim 12)
Third layer: exact medium selection
- Claims 5 and 13: FaSSIF Level 1 at pH ~6.5
- Claims 6 and 14: phosphate buffer at pH ~6.8
Fourth layer: surfactant-enabled simulation
- Claims 15-16: FaSSIF Level 1 includes added surfactant ~0.5 mg/mL
- Claims 17-18: phosphate buffer includes added surfactant ~0.5 mg/mL
- Claims 19-20 / 21-22: additional repeats of these same media-plus-surfactant conditions tied to earlier dependencies
Fifth layer: capsule size
- Claims 23-24: capsule is size 1
Sixth layer: polymer fraction and fixed-point blend ratios
- Claim 8: polymer blend fraction 6 wt.% to 13 wt.% of coated core weight
- Claim 9: fixed-point polymer blend fraction 9.1 wt.% (±2%) of total coated core weight
- Claim 25: repeats the 6 wt.% to 13 wt.% range as a dependent claim on claim 1
- Claim 26: “locking” set of fixed values:
- Ethylcellulose 51.8 wt.% (±2%)
- HPMC 27.3 wt.% (±2%)
- Polymer blend fraction 9.1 wt.% (±2%)
- Capsule size 1
Engineering Scope: What the Claims Actually Require (and How Competitors Can Miss It)
1) Acid resistance (pH 1.2) is capped
The formulation must show:
- ≤10% budesonide release within 120 minutes at pH ~1.2 in the USP <711> Apparatus 2 paddle test (100 rpm)
This blocks competitors from arguing general enteric protection; the claim demands a specific release outcome in a standardized test.
2) Early intestinal release is capped at 30 minutes
At intestinal pH simulation:
- ≤10% released within 30 minutes in either:
- FaSSIF Level 1 pH ~6.5, or
- phosphate buffer pH ~6.8
This is a second gate. Even if acid release is low, a formulation that releases too quickly post-entry falls outside.
3) Substantial extended release is required by 120 minutes
Still at intestinal pH simulation:
- ≥70% released within 120 minutes
The design has to balance “not too fast early” and “complete enough by 2 hours,” which narrows formulation approaches that either:
- dump quickly (violates the ≤10% @30 min), or
- release too slowly (violates the ≥70% @120 min).
4) Polymer blend composition is a defining structural parameter
Two different “independent claim tracks” appear:
- Track A (Claim 1): fixed blend components at ~51.8 wt.% ethylcellulose and ~27.3 wt.% HPMC (as wt.% of the extended-release polymeric blend), with polymer blend fraction 5 to 18 wt.% of coated core weight.
- Track B (Claim 7): broader ethylcellulose/HPMC windows (47–56 wt.% ethylcellulose; 32–22 wt.% HPMC) with same polymer blend fraction window.
5) Polymer blend loading is not an open ended “coating exists”
The claims require the extended-release polymeric blend is 5 wt.% to 18 wt.% of total coated core weight, with additional dependent limitations:
- 6–13 wt.% (claims 8 and 25)
- 9.1 wt.% ±2% (claim 9)
- or the fully locked set with (claim 26) fixed blend component ratios plus the locked polymer blend fraction plus size 1 capsule.
6) Ileum-region outcome is a key narrowing outcome
Claims 2-4 and 10-12 require substantial release in the ileum region, with quantitative thresholds:
- ≥60% (claims 3 and 11)
- ≥90% (claims 4 and 12)
This is an enforcement pressure point. Competitors may meet dissolution in vitro but miss site-selective release in vivo.
Scope Map: Claim-to-Design “Hit or Miss” Matrix for Developers
Direct claim elements and likely design levers
| Claim element |
Literal requirement (as provided) |
Likely formulation/design lever |
Where competitors can miss |
| Enteric + core coating |
Oral capsule with enteric coating 34–46 mg/capsule; core coated with extended-release polymer blend |
Enteric mass and polymer coating on budesonide cores |
Using enteric coating but with different mass or relying on unquantified coating performance |
| Acid release gate |
≤10% released at pH 1.2 within 120 min |
Film permeability and enteric integrity |
Coatings that leak early or different polymer matrices affecting diffusion in acidic media |
| Intestinal early release gate |
≤10% released in ≤30 min at pH 6.5 or 6.8 |
Polymer erosion/diffusion kinetics |
Faster erosion polymers, insufficient coating mass, or different blend ratio |
| Extended release completion |
≥70% released by 120 min at intestinal pH |
Release kinetics tuned for 2-hour window |
Too-slow systems that don’t reach 70% by 120 min |
| Polymer blend composition |
Ethylcellulose and HPMC wt.% values in the blend (fixed in claim 1/26; ranged in claim 7) |
Blend formulation |
Different ratios that still look “close” but fall outside numeric windows |
| Polymer blend fraction |
5–18 wt.% (or narrower dependent ranges) of coated core weight |
Coating weight fraction |
Slightly higher or lower coating fraction |
| Ileum targeting |
“Substantially released to ileum” with ≥60% or ≥90% thresholds |
Site targeting and enteric behavior |
Achieving dissolution but not ileum localization in vivo |
| Simulation medium specificity |
FaSSIF Level 1 pH 6.5 or phosphate buffer pH 6.8 |
Choice of test medium |
Different media compositions or omission of surfactant condition when invoked |
| Surfactant condition |
Added surfactant ~0.5 mg/mL in specified media |
In vitro test setup |
Different surfactant level or different “Level” designation |
| Capsule size |
Size 1 capsule |
Manufacturing form factor |
Different capsule size if asserted in dependent claims |
Patent Landscape: Practical Positioning Versus Likely Design-Around Space
What this patent blocks
As written, 11,896,719 blocks therapeutic claims that combine:
1) IgA nephropathy treatment with budesonide, and
2) an oral capsule delivery system that satisfies the exact USP <711> App. 2 dissolution performance gates, and
3) a coated core using the specified ethylcellulose/HPMC extended-release blend with constrained weight fraction, and
4) (in later dependents) ileum-region release percentages.
That creates a relatively narrow “claim corridor.” A competitor must either:
- replicate the dissolution profile tightly, and
- hit the polymer blend numbers, or
- avoid the claim by changing at least one “numeric gate” so that the dissolution criteria and/or polymer composition falls outside.
How dependent claims expand enforcement
Dependent claims create multiple ways to land on infringement depending on formulation characteristics:
- Even if a product misses claim 1 fixed ratios, it can still land under claim 7 broad polymer ranges.
- If a product’s dissolution kinetics align but ileum targeting differs, it may still face exposure under the non-ileum claims (1 or 7) but potentially escape those dependents (2-4, 10-12).
- If a product uses specific simulation media with surfactant, it can be brought under 15-22 if the media matches the surfactant specification.
- If capsule form factor differs (not size 1), it avoids 23-24 and the tight locked configuration 26 while still potentially meeting the broader dissolution/polymers unless those dependents are asserted.
Design-around levers that most directly affect literal claim elements
Based on the claim text alone, the most “literal” escape levers are:
- Shift dissolution timing outside the windows:
- make acid release exceed 10% by 120 min, or
- make intestinal early release exceed 10% by 30 min, or
- make intestinal release fall below 70% by 120 min.
- Change the polymer blend composition or its fraction:
- move ethylcellulose/HPMC ratios outside the windows (claim 1 fixed; claim 7 ranged; claim 26 fixed ±2%).
- move polymer blend loading outside 5–18 wt.% (or narrower 6–13, 9.1 ±2%).
- Change capsule parameters:
- avoid enteric coating mass 34–46 mg per capsule
- use a capsule size other than size 1 if the narrower dependents are asserted.
- Change site-release behavior:
- if in vivo ileum release cannot reach ≥60% or ≥90%, those dependents are harder to prove.
Claims as an Enforcement Tool: Why this is “Spec-Heavy” rather than “Genus-Heavy”
The claims do not read as “any modified-release budesonide capsule.” They read as:
- a specific polymer chemistry pairing (ethylcellulose + HPMC) with explicit blend proportions,
- a specific amount of that polymer blend within the coated core,
- a standardized in vitro release performance profile with numeric cutoffs,
- a standard enteric coating mass per capsule, and
- a standard daily dose (about 16 mg).
For infringement analysis, the practical consequence is that any challenger needs to evaluate the product against the full combined set of numeric requirements. Partial overlap is unlikely to neutralize the claim unless the product cleanly misses one of the hard gates.
Key Takeaways
- US 11,896,719 is a method-of-use patent for IgA nephropathy using orally administered budesonide with a spec-defined enteric capsule and extended-release coated core.
- The patent scope is defined by numeric dissolution thresholds under USP <711> App. 2 at 100 rpm, including:
- ≤10% release at pH 1.2 by 120 min
- ≤10% release at pH 6.5 FaSSIF Level 1 or pH 6.8 phosphate buffer by 30 min
- ≥70% release at the same intestinal media by 120 min
- The formulation must include an ethylcellulose/HPMC extended-release polymer blend with constrained:
- component ratios (fixed in claim 1 and locked in claim 26; ranged in claim 7),
- blend loading as % of coated core weight (5–18 wt.% base; narrowed to 6–13 or 9.1 ±2% in dependents).
- Dependent claims add ileum-region release thresholds (≥60% or ≥90%) and specific dissolution media variants (FaSSIF Level 1 pH 6.5, phosphate pH 6.8, with 0.5 mg/mL surfactant when invoked), plus size 1 capsule constraints.
FAQs
1) Is 11,896,719 broad across all budesonide IgA therapies?
No. It requires budesonide delivery that meets the specific polymer blend plus the USP <711> dissolution release profile under Apparatus 2 (paddle, 100 rpm) with tight numeric caps at pH 1.2 and intestinal pH.
2) What is the hardest “literal” element to design around?
The combined set of numeric dissolution gates plus the polymer blend composition and loading. Missing any one hard gate can move the product outside the claim.
3) Do the claims require in vivo proof of ileum release?
The dependent claims require the method as reciting ileum-region release thresholds (≥60% or ≥90%), which effectively ties infringement to ileum localization behavior in addition to dissolution test performance.
4) Does the patent allow both FaSSIF and phosphate buffer as the intestinal medium?
Yes. The claims state the pharmaceutically-relevant dissolution medium can be FaSSIF Level 1 at pH ~6.5 or phosphate buffer at pH ~6.8, and they further add surfactant specifics when those dependents are invoked.
5) How do capsule specifications affect infringement risk?
The claims include dependent limitations for size 1 and a required enteric coating mass per capsule (34–46 mg). Products that use different capsule size or enteric mass can avoid those dependents while still potentially facing the broader claim elements.
References
[1] USP <711> Dissolution (apparatus and testing framework), United States Pharmacopeia (as referenced in the claim language).
